MedTrace Logo

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

NCT03889275 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2023-02-21

No results posted yet for this study

Summary

The reason for the study is to find out if MEDI5395 and durvalumab will work and be safe for the treatment of solid tumors.

Conditions

Interventions

BIOLOGICAL

MEDI5395

Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.

BIOLOGICAL

Durvalumab

Participants will receive IV infusion of durvalumab as stated in arm description.

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Medimmune LLC · MedImmune LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
101 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-24
Primary Completion
2021-11-19
Completion
2022-12-12
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03889275 on ClinicalTrials.gov